Page last updated: 2024-09-04

torcetrapib and Disease Models, Animal

torcetrapib has been researched along with Disease Models, Animal in 7 studies

Research

Studies (7)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	1 (14.29)	29.6817
2010's	5 (71.43)	24.3611
2020's	1 (14.29)	2.80

Authors

Authors	Studies
Abrams, RPM; Bachani, M; Balasubramanian, A; Brimacombe, K; Dorjsuren, D; Eastman, RT; Hall, MD; Jadhav, A; Lee, MH; Li, W; Malik, N; Nath, A; Padmanabhan, R; Simeonov, A; Steiner, JP; Teramoto, T; Yasgar, A; Zakharov, AV	1
Briand, F; Costard, C; Muzotte, E; Prunet-Marcassus, B; Sordello, S; Sulpice, T; Thieblemont, Q	1
Barter, PJ; Kastelein, JJ; Nicholls, SJ; Rye, KA	1
Boekholdt, SM; Hovingh, GK; Ray, KK	1
Di Bartolo, B; Duong, M; Nicholls, SJ; Takata, K	1
Briand, F; Muzotte, E; Sulpice, T; Thieblemont, Q	1
Stein, O; Stein, Y	1

Reviews

2 review(s) available for torcetrapib and Disease Models, Animal

Article	Year
CETP Inhibition in CVD Prevention: an Actual Appraisal. Current cardiology reports, 2016, Volume: 18, Issue:5 Topics: Animals; Anticholesteremic Agents; Biomarkers; Cardiovascular Diseases; Cholesterol Ester Transfer Proteins; Cholesterol, LDL; Clinical Trials as Topic; Disease Models, Animal; Evidence-Based Medicine; Humans; Quinolines; Treatment Outcome	2016
Lipid transfer proteins (LTP) and atherosclerosis. Atherosclerosis, 2005, Volume: 178, Issue:2 Topics: Absorption; Animals; Arteriosclerosis; Carrier Proteins; Cholesterol; Cholesterol Ester Transfer Proteins; Clinical Trials as Topic; Disease Models, Animal; Enzyme Inhibitors; Epidemiologic Studies; Gene Transfer Techniques; Glycoproteins; Humans; Membrane Proteins; Mice; Oxidative Stress; Phosphatidylcholine-Sterol O-Acyltransferase; Phospholipid Transfer Proteins; Quinolines; Rabbits; Sterol O-Acyltransferase; Sterol O-Acyltransferase 2	2005

Article

Year

CETP Inhibition in CVD Prevention: an Actual Appraisal.

Current cardiology reports, 2016, Volume: 18, Issue:5

Topics: Animals; Anticholesteremic Agents; Biomarkers; Cardiovascular Diseases; Cholesterol Ester Transfer Proteins; Cholesterol, LDL; Clinical Trials as Topic; Disease Models, Animal; Evidence-Based Medicine; Humans; Quinolines; Treatment Outcome

2016

Lipid transfer proteins (LTP) and atherosclerosis.

Atherosclerosis, 2005, Volume: 178, Issue:2

Topics: Absorption; Animals; Arteriosclerosis; Carrier Proteins; Cholesterol; Cholesterol Ester Transfer Proteins; Clinical Trials as Topic; Disease Models, Animal; Enzyme Inhibitors; Epidemiologic Studies; Gene Transfer Techniques; Glycoproteins; Humans; Membrane Proteins; Mice; Oxidative Stress; Phosphatidylcholine-Sterol O-Acyltransferase; Phospholipid Transfer Proteins; Quinolines; Rabbits; Sterol O-Acyltransferase; Sterol O-Acyltransferase 2

2005

Other Studies

5 other study(ies) available for torcetrapib and Disease Models, Animal

Article	Year
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors. Proceedings of the National Academy of Sciences of the United States of America, 2020, 12-08, Volume: 117, Issue:49 Topics: Animals; Antiviral Agents; Artificial Intelligence; Chlorocebus aethiops; Disease Models, Animal; Drug Evaluation, Preclinical; High-Throughput Screening Assays; Immunocompetence; Inhibitory Concentration 50; Methacycline; Mice, Inbred C57BL; Protease Inhibitors; Quantitative Structure-Activity Relationship; Small Molecule Libraries; Vero Cells; Zika Virus; Zika Virus Infection	2020
Raising HDL with CETP inhibitor torcetrapib improves glucose homeostasis in dyslipidemic and insulin resistant hamsters. Atherosclerosis, 2014, Volume: 233, Issue:2 Topics: AMP-Activated Protein Kinases; Animals; Anticholesteremic Agents; Apolipoprotein A-I; Apolipoproteins E; Cholesterol Ester Transfer Proteins; Cholesterol, HDL; Cricetinae; Deoxyglucose; Diet, Atherogenic; Disease Models, Animal; Drug Evaluation, Preclinical; Dyslipidemias; Enzyme Activation; Feces; Glucose; Homeostasis; Hyperglycemia; Insulin Resistance; Male; Mesocricetus; Muscle, Skeletal; Quinolines; Random Allocation; Species Specificity	2014
Is Cholesteryl Ester Transfer Protein Inhibition an Effective Strategy to Reduce Cardiovascular Risk? CETP Inhibition as a Strategy to Reduce Cardiovascular Risk: The Pro Case. Circulation, 2015, Aug-04, Volume: 132, Issue:5 Topics: Amides; Animals; Anticholesteremic Agents; Benzodiazepines; Cardiovascular Diseases; Cholesterol Ester Transfer Proteins; Disease Models, Animal; Esters; Humans; Lipid Metabolism, Inborn Errors; Mice; Oxazolidinones; Quinolines; Rabbits; Risk Factors; Sulfhydryl Compounds; Treatment Outcome	2015
Is Cholesteryl Ester Transfer Protein Inhibition an Effective Strategy to Reduce Cardiovascular Risk? CETP as a Target to Lower CVD Risk: Suspension of Disbelief? Circulation, 2015, Aug-04, Volume: 132, Issue:5 Topics: Amides; Animals; Anticholesteremic Agents; Benzodiazepines; Cardiovascular Diseases; Cholesterol Ester Transfer Proteins; Disease Models, Animal; Esters; Humans; Lipid Metabolism, Inborn Errors; Mice; Oxazolidinones; Quinolines; Rabbits; Risk Factors; Sulfhydryl Compounds; Treatment Outcome	2015
Upregulating reverse cholesterol transport with cholesteryl ester transfer protein inhibition requires combination with the LDL-lowering drug berberine in dyslipidemic hamsters. Arteriosclerosis, thrombosis, and vascular biology, 2013, Volume: 33, Issue:1 Topics: Animals; Berberine; Biological Transport; Cholesterol; Cholesterol Ester Transfer Proteins; Cholesterol Esters; Cholesterol, HDL; Cholesterol, LDL; Cricetinae; Disease Models, Animal; Down-Regulation; Drug Therapy, Combination; Dyslipidemias; Feces; Hypolipidemic Agents; Kinetics; Lipoproteins, LDL; Liver; Liver X Receptors; Macrophages; Male; Mesocricetus; Orphan Nuclear Receptors; Quinolines; Up-Regulation	2013